Rhone-Poulenc Rorer ebastine
Executive Summary
Ebastine NDA receives "not approvable" letter from FDA for once-daily treatment of seasonal and perennial allergic symptoms March 31. RPR plans to file an amendment to the NDA for combination use with other drugs commonly prescribed to allergy sufferers, the company says